Tyme Technologies, Inc.
(NASDAQ : TYME)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Miscellaneous » Miscellaneous
symbolcompany%chnglast%shortavg$volume
XXII22nd Century Group, Inc.
1.94%2.373.9%$7.61m
TACODel Taco Restaurants, Inc.
0.33%12.228.4%$6.54m
RILYB. Riley Financial, Inc.
0.54%18.701.2%$1.81m
LINDLindblad Expeditions Holdings Inc
0.19%10.561.4%$1.20m
PANLPangaea Logistics Solutions Ltd.
-0.45%4.400.0%$0.92m
CCCLChina Ceramics Co. Ltd.
5.26%1.802.6%$0.87m
PMEPingtan Marine Enterprise Ltd.
2.63%3.120.9%$0.39m
SGOCSGOCO Group Ltd.
2.42%1.270.1%$0.32m
ABILAbility, Inc.
5.42%0.550.6%$0.19m
ZAISZAIS Group Holdings, Inc. Class A
5.38%3.923.9%$0.06m
RMGNRMG Networks Holding Corporation
0.00%1.030.2%$0.06m
ELECElectrum Special Acquisition Corp.
0.29%10.270.1%$0.01m
ELECUElectrum Special Acquisition Corp Units Cons of 1 Sh + 1 Wts
0.00%10.600.1%$0.01m
BHACBarington/Hilco Acquisition Corp
-4.91%10.450.0%$0.00m
BHACUBarington/Hilco Acquisition Corp Units Cons of 1 Sh + 1 Rt + 1 Wt
0.00%10.400.0%$0.00m

Company Profile

Tyme Technologies, Inc. is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use cancer's unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its first-in-human trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three-year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai and other institutions. Tyme Technologies was founded on November 22, 2011 and is headquartered in New York, NY.